Navigation Links
EMAS publishes position statement about the post-reproductive health of women
Date:5/17/2011

Amsterdam, 17 May 2011 - Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society (EMAS) in the journal Maturitas (http://www.maturitas.org/) on managing menopausal women with a personal or family history of venous thromboembolism (VTE). The statement includes summary recommendations as a quick aid for the busy clinician.

"The expanding ageing female population means that clinicians increasingly have to deal with post-reproductive health problems," said Professor Serge Rozenberg, President of EMAS. "EMAS has risen to the challenge and is providing clear guidance on the position statements covering hormone and non hormone therapy (HT) options, as well as complementary and alternative therapies."

The statement will be published in the June 2011 issue:

Venous thromboembolism, including deep venous thrombosis (DVT) and pulmonary embolism (PE), is a serious cardiovascular event whose incidence rises with increasing age. Randomized controlled trials have shown an increased risk of VTE in oral hormone therapy (HT) users. There are no randomized trial data on the effect of transdermal estrogen on VTE. Recent observational studies and meta-analyses suggest that transdermal estrogen does not increase VTE risk. These clinical observations are supported by experimental data showing that transdermal estrogen has a minimal effect on hepatic metabolism of hemostatic proteins as the portal circulation is bypassed.

A personal or family history of VTE, especially in individuals with a prothrombotic mutation, is a strong contraindication to oral HT but transdermal estrogen can be considered after careful individual evaluation of the benefits and risks. Transdermal estrogen should be also the first choice in overweight/obese women requiring HT. Observational studies suggest that micronized progesterone and dydrogesterone might have a better risk profile than other progestins with regard to VTE risk.

Although these findings should be confirmed by randomized clinical trials, they strongly suggest that both the route of estrogen administration and the type of progestin may be important determinants of the overall benefit-risk profile of HT.


'/>"/>

Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Source:Eurekalert

Related medicine news :

1. ASTRO publishes evidence-based guideline for thoracic radiotherapy
2. Canadian Journal of Cardiology publishes advice on genetic testing of inherited cardiac arrhythmias
3. NYSCF - Robertson investigator publishes research to better understand pluripotent stem cells
4. ASTRO publishes palliative radiotherapy for bone metastases guideline
5. Practical Radiation Oncology publishes first issue
6. EMAS publishes position statements about the post-reproductive health of women
7. ASTRO publishes whole breast irradiation guidelines
8. ESMO publishes updated guidelines on cancer care
9. US Medical Supplies Publishes 2010 Catalog
10. AACR Adds to Growing STAR P-2 trial; Publishes Update and Perspectives in Cancer Prevention Research
11. Better Hearing Institute Publishes Comprehensive Consumer Guide to Buying Hearing Aids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: